The ATACC-RA consortium has entered an independent cooperation agreement with Lilly from 1. January 2016 till 31. December 2017, where Lilly is a project contributor to the consortium. This agreement is not in any way (directly or indirectly) entered into conditional upon that the Consortium, or any of their participants, shall recommend, prescribe, purchase, sell or administrate certain pharmaceuticals, and that no efforts will be made by Lilly in connection with this agreement to influence the operations of the Consortium.
An agreement on future cooperation, similar to the one above, between the ATACC-RA consortium and Lilly has been reached. Specifics on this agreement will be updated soon.